Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mingjin Yan

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Biometrics|April 12, 2007
Determining the number of clusters using the weighted gap statisticMingjin Yan, Keying Ye
Frontiers in Psychology|July 10, 2026
Physical exercise and subjective wellbeing among Chinese students in South Korea: the mediating roles of exercise-related psychological needs satisfaction and psychological resilienceShang Gao, Mingjin Yan, Xinxin Zhang, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|August 18, 2012
Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trialLeszek Bidzan, Atul R Mahableshwarkar, Paula Jacobsen, et al.
The Anatomical Record. Part A, Discoveries in Molecular, Cellular, and Evolutionary Biology|November 1, 2006
Valproic acid-induced fetal malformations are reduced by maternal immune stimulation with granulocyte-macrophage colony-stimulating factor or interferon-gammaTerry C Hrubec, Mingjin Yan, Keying Ye, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|August 21, 2012
Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United StatesAnthony J Rothschild, Atul R Mahableshwarkar, Paula Jacobsen, et al.
HIV Clinical Trials|March 18, 2017
Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial<sup/>Frank A Post, Yazdan Yazdanpanah, Gabriel Schembri, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 19, 2016
A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected AdultsGregory D Huhn, Pablo Tebas, Joel Gallant, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 9, 2017
Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed AdultsFrançois Raffi, Chloe Orkin, Amanda Clarke, et al.
The Lancet. HIV|April 3, 2016
Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trialJoel E Gallant, Eric S Daar, François Raffi, et al.
The Lancet. HIV|February 25, 2018
Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trialAlan Winston, Frank A Post, Edwin DeJesus, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Biometrics|April 12, 2007
Determining the number of clusters using the weighted gap statisticMingjin Yan, Keying Ye
Frontiers in Psychology|July 10, 2026
Physical exercise and subjective wellbeing among Chinese students in South Korea: the mediating roles of exercise-related psychological needs satisfaction and psychological resilienceShang Gao, Mingjin Yan, Xinxin Zhang, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|August 18, 2012
Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trialLeszek Bidzan, Atul R Mahableshwarkar, Paula Jacobsen, et al.
The Anatomical Record. Part A, Discoveries in Molecular, Cellular, and Evolutionary Biology|November 1, 2006
Valproic acid-induced fetal malformations are reduced by maternal immune stimulation with granulocyte-macrophage colony-stimulating factor or interferon-gammaTerry C Hrubec, Mingjin Yan, Keying Ye, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|August 21, 2012
Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United StatesAnthony J Rothschild, Atul R Mahableshwarkar, Paula Jacobsen, et al.
HIV Clinical Trials|March 18, 2017
Efficacy and safety of emtricitabine/tenofovir alafenamide (FTC/TAF) vs. emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active-controlled phase 3 trial<sup/>Frank A Post, Yazdan Yazdanpanah, Gabriel Schembri, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 19, 2016
A Randomized, Open-Label Trial to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Darunavir in Treatment-Experienced HIV-1-Infected AdultsGregory D Huhn, Pablo Tebas, Joel Gallant, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|March 9, 2017
Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed AdultsFrançois Raffi, Chloe Orkin, Amanda Clarke, et al.
The Lancet. HIV|April 3, 2016
Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trialJoel E Gallant, Eric S Daar, François Raffi, et al.
The Lancet. HIV|February 25, 2018
Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trialAlan Winston, Frank A Post, Edwin DeJesus, et al.
Pageof 2